AngioDynamics, Inc. (ANGO) Publishes Pancreatic IRE Data, Wins New CPT Code
AngioDynamics reported study results linking IRE to longer survival in Stage III PDAC. The AMA approved a new CPT code for open pancreatic IRE, effective 2027. The company aims to strengthen IRE's clinical and reimbursement foundation.
How this was made
The 30-second read
Why it matters
The new CPT code could unlock reimbursement, supporting revenue growth once the therapy is widely adopted.
Market read
First report of trial data and CPT code approval provides a material catalyst for ANGO.
What to watch
Reimbursement adoption depends on payer negotiations and further trial validation.
Background
AngioDynamics focuses on irreversible electroporation (IRE) technology, currently expanding from prostate to pancreatic cancer.
Ticker impact
AngioDynamics announced publication of IRE trial data for pancreatic cancer and received a new CPT code approval effective Jan 1, 2027.
likely upside as market prices in potential revenue from the new CPT code
Positive clinical data and a new reimbursement pathway are material catalysts for a medical device company.
Market effects
May improve outlook for interventional oncology devices and related reimbursement trends.
US healthcare sector could see modest uplift.
Limited to markets where CPT coding is applicable.
Counterpoint
The CPT code is effective only in 2027; investors may overprice near-term expectations.
Key entities
- CompanyAngioDynamics, Inc.
Medical device company developing IRE technology.
